ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE




Dr Muhammad Waqar Nazir, Dr Rizwan Ul Husnain, Dr Minahil Haq


Introduction: Despite the use of plasma exchanges and intravenous immunoglobulins, Guillain-Barré syndrome (GBS) still carries non-negligible morbidity and mortality. Furthermore, the psychosocial consequences of GBS may persist longer than expected. Aims and objectives: The basic objective of the study is to analyze the level of hypoalbuminemia as prognostic indicator in GBS patients among local population of Pakistan. Material and methods: This descriptive study was conducted in Nishter Hospital Multan during January 2019 to July 2019. The data were collected from 50 patients of GBS which also include adults and child. The data were divided into two parts one include adults and one group include children. Venous blood samples were drawn from all patients within the first 24 hours after admission. Complete blood count, renal function test, and hepatic function test were performed within 24 hours of hospital admission and before the treatment, and serum CRP, albumin, neutrophil, lymphocyte, thrombocyte, CRP, NLR, and PLR levels were recorded. Results: The data were collected from 50 GBS patients. The mean age was 48.5±18.95 years in adults and 5±8.21 years in GBS-P. No significant relationship was found between NLR, PLR, CRP, and albumin levels and the demyelinating and axonal subtypes in both the GBS-A and GBS-P patient groups. In the GBS-P group, on the other hand, the mean NLR level at third month was significantly higher in the HDS≥3 group, but there was no significant difference with the other inflammatory markers. Conclusion: It is concluded that inflammatory markers including and albumin levels may be used as cheaper, more readily available, and more rapidly studied markers for the prediction of the prognosis of GBS.


  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.